GlassScriptPhysician profile
Marina G Shtern
NPI 1093870388
$1,136.83
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $427 · 2020: $236 · 2021: $432 · 2022: $41.63.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $709.71 | 2019-2021 | |
| Evofem Biosciences, INC. | $130.84 | 2020-2021 | |
| Millicent US INC | $53.99 | 2019-2020 | |
| Myovant Sciences INC. | $47.80 | 2021 | |
| Amag Pharmaceuticals, INC. | $46.22 | 2019 | |
| Scynexis, INC. | $41.63 | 2022 | |
| Avion Pharmaceuticals | $26.32 | 2019-2020 | |
| Therapeuticsmd, INC. | $23.66 | 2020 | |
| Agile Therapeutics, INC. | $20.74 | 2021 | |
| Vertical Pharmaceuticals, LLC | $20.20 | 2019 | |
| Roche Diagnostics Corporation | $15.72 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marina Shtern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.